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Background: Fibromyalgia (FM) is a debilitating syndrome, more prevalent in women,
which is aggravated by the presence of depressive symptoms. In the last decade, cognitive
behavioral therapy (CBT) has demonstrated to reduce such depressive symptoms and pain in
these patients, but there are still a considerable number of them who do not respond to
interventions. The complexity of the disorder requires the consideration of the unique
psychological characteristics of each patient to attain good outcomes. One approach that
could accomplish this goal might be personal construct therapy (PCT), an idiographic
approach that considers identity features and interpersonal meanings as their main target of
intervention. Then, the aim of the study is to test the efficacy of PCT as compared to a well-
established treatment in the reduction of depressive symptoms in women with fibromyalgia.
Methods and Analysis: This is a multicenter randomized controlled trial. In each condition
participants will attend up to eighteen 1-hr weekly therapy sessions and up to three 1-hr booster
sessions during the following 3–5 months after the end of treatment. The depression subscale
of the Hospital Anxiety and Depression Scale (HADS-D) will be the primary outcome measure
and it will be assessed at baseline, at the end of therapy, and at 6-month follow-up. Other
secondary measures will be applied following the same schedule. Participants will be 18- to
70-years-old women with a diagnosis of FM, presenting depressive symptoms evinced by
scores above seven in depression items of the HADS-D. Intention-to-treat and complete case
analyses will be performed for the main statistical tests. Linear mixed models will be used to
analyze and to compare the treatment effects of both conditions.
Trial Registration: ClinicalTrials.gov: NCT02711020.
Keywords: psychotherapy, pain, repertory grid technique, study protocol, CBT, personal
construct therapy
Introduction
Fibromyalgia (FM) is a syndrome characterized by the presence of generalized and
chronic musculoskeletal pain. It is the most common pain condition and it is
the second most frequent rheumatic disorder.1 The worldwide prevalence is
approximately 2.7%.2 In Spain, the reported prevalence ranged from 2.3% to
2.7%, and it is more prevalent in females (3.3–4.2%) than in males (0.2–1.3%).3,4
Patients with FM indicate that they experience significantly more intense pain than
patients with other pain conditions.5,6 FM has a high comorbidity of psychiatric issues,
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especially of affective disorders.7 Major depression disorder
seems to be the most frequent diagnosis with a lifetime pre-
valence ranging from 62% to 86%, but depressive symptoms
are present for 90% of the patients.8 These patients with both
FM and depressive symptoms exhibit lower levels of physical
functioning and worse quality of life than those without
depressive symptoms.9,10 The presence of depressive symp-
toms at the onset of development of the syndrome predicts
limited treatment response in terms of pain intensity
reduction.11 In general, these data confirm that symptoms of
depression exacerbate and aggravate the chronic course of the
disease; and as a result, patients presenting both conditions
consume more health-care resources, even considering the
additional cost of each condition when diagnosed separately.12
Generally, the accepted objectives for the treatment of FM
are to relieve pain, to acquire emotional balance, to improve
physical activity, and other associated problems.13,14
Nowadays, strong evidence exists in favor of multidisciplinary
treatment, which might include medication, education about
the syndrome, moderate physical activity and psychological
interventions.1,15 In relation to psychological interventions, an
extensive review conducted by Glombiewski et al16 indicates
the presence of small effect sizes related to pain reduction, both
at short- and long-term measurement. All the included treat-
ments show similar efficacy in the reduction of depressive
symptoms, although cognitive behavioral therapy (CBT) pre-
sented the greatest effect sizes regarding short-termpain reduc-
tion. Another meta-analysis17 assessing only CBT supports its
effects on improving self-efficacy, pain, and depressive symp-
toms, but yields small effect sizes for pain reduction and for
improving the quality of life.
After several decades of studies about treatments for FM,
one of the main limitations which have been recognized is the
underestimation of the complexity of the disorder, resulting in
a lack of specificity of the treatments.18 It is essential to identify
which psychological profiles respond to specific
treatments.19,20 Treatments should adapt to the needs and
specific psychological features of the patients, taking into
consideration their physical functioning and, especially, their
depressive symptoms.13,21,22 Although brief structured group
therapy has been the predominant psychological treatment for
FM, individual psychotherapy seems to produce greater effects
for this population.21 Furthermore, long-term psychological
treatments display bigger effect sizes for pain reduction and
improvement of depressive symptoms.16 Overall, long-term
psychological treatments that take into account the unique
psychological characteristics [eg,23,24] of each patient might
be in a better position to attain good outcomes. Also, the focus
on specific behaviors, thoughts and emotions that characterizes
CBT has proved insufficient in its efficacy and we expect that
a therapeutic approach addressing the impact on the person’s
self-identity of developing an FM syndrome might be more
efficacious at least in decreasing depressive symptoms. One
approach that could accomplish this goal might be personal
construct therapy (PCT),23,24 an idiographic approach that
considers identity features and interpersonal meanings as
theirmain target of intervention. Every person construes (inter-
prets) events in different manners according to their own
cognitive system.25 PCT is aimed at reconstructing meanings
about self, significant others, and relevant events. Several
meta-analyses show some favorable evidence with respect to
its efficacy.26,27 It produces better outcomes than waiting list
and usual care conditions, but results are equivalent when
compared with active treatments. Also, at follow-up, patients
who were treated with PCT showed better results than those
who did not receive any active treatment.
PCT has devised assessment tools to assess people’s
construction of self and others. One of these instruments is
the repertory grid technique (RGT).28,29 This instrument
allows assessing self-concept and cognitive structure based
on the interviewee’s evaluation of their self, their significant
others, and their ideal-self by means of their own personal
constructs. Personal constructs are bipolar discriminations
(eg, “happy vs sad”) of how individuals describe themselves
and others.23 The person’s ratings of the self, ideal-self and
others (here termed elements in columns) according to their
personal constructs (in rows) form a data matrix, each cell
reflecting the rating of each element with regard to each
construct using a seven-point Likert scale. Although RGT
emphasizes idiographic information (i.e., the constructs eli-
cited from the person and their application to the elements),
some general cognitive measures can be obtained, including
current-self and ideal-self discrepancy, polarized and/or uni-
dimensional construing, and the presence (and number) of
cognitive conflicts. RGT has already been applied to under-
stand the personal constructions of patients with depression30
and of thosewith FM,31,32 among other conditions33. Patients
with depression showed negative self-evaluation, perceived
isolation and evaluate others negatively. In addition, they
present a greater proportion of implicative dilemmas, a type
of cognitive conflict in which the symptom is associated with
positive personal characteristics of the identity.34 Similarly,
for women with FM, we found higher self-ideal discrepancy,
as well as a more negative evaluation of others, as compared
to controls. Moreover, 76.7% of the clinical sample presented
implicative dilemmas, compared with 46.6% of the control
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group.31 When assessing the cognitive structure of patients
presenting both, depression and FM, the results indicated that
these patients presented greater cognitive rigidity and lower
differentiation than patients with depression without FM.32
The application of PCT for fibromyalgia using RGT
information to conduct the therapy has been tested in
a pilot study with 20 women with FM.35 Higher improve-
ment was observed in those with a history of maltreatment.
Interestingly, these women also had a greater depressive
symptomatology at the beginning of therapy. One ingredi-
ent of PCT is the work aimed at the resolution of impli-
cative dilemmas,36,37 the efficacy of this intervention for
depression has been tested in a randomized controlled
trial.38 The results showed that the inclusion of an indivi-
dual dilemma focused intervention to group CBT interven-
tion produced a big effect size for the reduction of
depressive symptoms (Cohen’s d = 1.13), and this effect
was comparable with the intervention with group CBT
plus individual CBT (Cohen’s d = 1.02).39
The research question we want to address in this study
refers to the efficacy of PCTas compared to a well-established
treatment in the reduction of depressive symptoms in women
with fibromyalgia. CBT has been chosen as the comparison as
it is the most studied psychological treatment16 and it is
recommended as a treatment of choice in all the reviews and
clinical guidelines.1,15 Given the promising evidence of
a previous pilot study,35 we expect that PCT will be more
efficacious in the reduction of depressive symptoms in
women with FM.
Specific Objectives
● To determine whether or not PCT is more efficacious
than CBT in the reduction of depressive symptoms of
women with FM.
● To compare the impact of PCT and CBT on variables
such as functional capacity, well-being and quality of
life of women with FM.
● To contrast the change in cognitive features (eg,
cognitive conflicts, polarization) assessed with the
RGT between both therapy conditions.
● To identify the baseline variables which predict common
and differential outcomes between both treatments.
Methods and Analysis
Design
This is a multicenter randomized, controlled parallel group,
two-arm, superiority trial to compare the efficacy of individual
PCT with individual CBT for reduction of depressive symp-
toms inwomenwith FM.The allocation ratio for this trial is 1:1
(see Figure 1 for trial design). This design not only permits the
comparison between treatments but also allows identification
of the personal characteristics of those patients who attain
better outcomes.
Settings
This study is conducted at nine mental health centers, with
different levels of attention: Nou Barris Nord Mental
Health Center (CSMA Nou Barris Nord), Hospital de
Mataró, and primary care centers such as CAP Manso
(Institut Català de la Salut, Barcelona), CAP Les Hortes
(EAP PobleSec), and five primary care centers in
Badalona (Badalona Serveis Assistencials).
Participants
Only female adult patients diagnosed with fibromyalgia by
professionals of the health system are included because data
show a small percentage of males diagnosed with FM3,4 and,
therefore, it is easier to contact and identify female patients
within the centers. The decision was taken to maintain the
homogeneity of the sample for the statistical analyses.4
Inclusion Criteria
Participants will bewomenwith a diagnosis of FMand depres-
sive symptoms as evinced by a score above seven in the
depression items of the Hospital Anxiety and Depression
Scale (HADS-D).40 The age of participants will range from
18 to 70 years, since this range concentrates most of the
incidence of FM patients.4
Exclusion Criteria
Patients are excluded from the study if they present bipolar
disorders, psychotic symptoms, substance abuse, acute suicidal
ideation, intellectual disability or organic brain dysfunction.
Also, patients are not accepted if they are receiving psycholo-
gical treatment, unless it is suspended (agreement with the
patient and their therapist) at the time of inclusion in the
study. Finally, those who do not have enough level of compe-
tence to communicate in Spanish or Catalan, or patients with
substantial visual, hearing and cognitive deficits are not
included. The comorbid occurrence of other conditions and
consumption of psychotropic drugs are assessed and recorded
for statistical control, but they are not causes for exclusion.
The sample size for this study was calculated with regard to
themean comparison between treatment conditions considering
an effect size of at least 0.30 to accept the alternative hypothesis
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that PCTsignificantly reduces depressive symptoms in compar-
ison to CBT. With a statistical power of 0.80, a Type 1 error
level of 5% (one-sided), assuming an estimated common stan-
dard deviation of 1, and a correlation betweenmeasurements of
0.85; a total sample of 90 patients is required, 45 patients in
each condition. We expect to have a dropout rate of 20%, then
a total of 112 patients will be recruited (56 in each condition).
Participant Allocation
Once the baseline assessment is completed, women who
meet the criteria to be part of the study are randomly allo-
cated to one of the two treatment conditions (CBT or PCT).
The randomization is performed by a staff member of the
Universitat de Barcelona (not involved in the trial and blind
to treatment conditions) using a computer-generated alloca-
tion permuted block sequence, stratified by type of center
(mental health/primary care) in which the participants are
recruited. Treatments are conducted in same center in which
the participant receives treatment for FM.
Treatments
Two individual-format psychological treatments are applied,
with a limit of eighteen 1-hr sessions. A maximum of three
1-hr booster sessions can be done according to each patient’s
needs in the 3–5 months following the end of the treatment.
t1: Baseline Assessment (session 1): HADS-D, HADS-A, 
Sociodemographic and clinical information, HDRS, FIQ Excluded: HADS-D > 7
Randomization
t1: Baseline Assessment (session 2): RGT and CORE-OM
t2: Post-treatment Assessment: HADS-D, HADS-A, HDRS, 
FIQ, RGT and CORE-OM
Excluded: bipolar disorders, psychotic symptoms, 
substance abuse, acute suicidal ideation, 
intellectual disability, organic brain dysfunction 
and receiving another psychological treatment
Recruitment: Adult female FM patients (18-70 years old) 
presenting depressive symptoms
t3: Follow-Up Assessment (6 months after therapy):
HADS-D, HADS-A, HDRS, FIQ and CORE-OM
Individual PCT
Up to 18 1-hour sessions 
CORE-SFB and VAS Pain
Individual CBT
Up to 18 1-hour sessions 
CORE-SFB and VAS Pain
Booster sessions PCT 
Up to 3 1-hour sessions. 
CORE-SFB and VAS Pain
Booster sessions CBT 
Up to 3 1-hour sessions. 
CORE-SFB and VAS Pain
Figure 1 Flow chart diagram of the trial design.
Abbreviations: PCT, Personal Construct Therapy; CBT, Cognitive Behavioral Therapy; HADS-D, Hospital Anxiety and Depression Scale – Depression; HADS-A, Hospital
Anxiety and Depression Scale – Anxiety; HDRS, Hamilton Depression Rating Scale; FIQ, Fibromyalgia Impact Questionnaire; RGT, Repertory Grid Technique; CORE-OM,
Clinical Outcomes in Routine Evaluation – Outcome Measure.
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Both interventions are based on case conceptualization; then,
the number of sessions rely on the goals set up for each
patient by their assigned therapist. Contents of session, tech-
niques, and procedures depend on the applied condition, as
follows.
Cognitive Behavioral Therapy (CBT)
The applied techniques and interventions for this condition
are adaptations of methods already used with FM patients
in the CBT group format:
Psychoeducation
It includes information about FM, different means to cop-
ing with the condition and the influence of depression and
anxiety, muscular tension, inactivity, and distorted thinking
in the genesis and maintenance of pain.41
Relaxation
Techniques such as diaphragmatic breathing and progres-
sive muscle relaxation are offered to cope with pain.
Behavioral Activation
Different elements about behavior are managed consider-
ing the relation between inactivity, emotions and thoughts
associated to depression and FM. To produce activation of
the patients, behavioral records are used in companion to
task prioritization and gradual involvement in pleasant
activities.42,43
Cognitive Restructuring
This module focuses on the relationship between thoughts,
emotions and behaviors. The emphasis is on the link
between emotions and body reactions. Also in the identi-
fication and modification of automatic thoughts and beliefs
that are related with depression and FM.43
The order and the degree in which these modules are
applied varies in order to adapt to the needs of every patient.
Personal Construct Therapy
The protocol for this condition was specifically designed
for the present trial based on previous literature regarding
case formulation according to TCP44 and our prior experi-
ence in a pilot study.35 Four possible courses of action
with specific objectives and techniques have been defined
from common motives for consultation presented in the
pilot study and observed in our clinical practice. In the first
two sessions, therapists explore the patients’ demands or
complaints, their theory of the problem, and the possible
solutions they have thought of. Our treatment model
considers that patients evolve along the therapy; therefore,
it is reasonable to address more than one course of action.
Complaints Focused on Pain
In these cases, patients’ narratives revolve around the
symptoms of the FM and, generally, they do not recognize
any other problem. The objective of the intervention is to
enrich and to nuance the construct “pain-without pain”, as
well as to promote the inclusion of other constructs in the
explanation of the events and in the construction of their
personal and corporal experience. The techniques used
with them are mainly the psychoeducation with regard to
gate control theory of pain45 and the externalization of
pain using letters to the pain or draws.
Complaints Focused on Emotional Avoidance
In these cases, the expressed wish is “to stop feeling”.
Taking into consideration the construing processes involved
in this complaint, we conceptualize it as a process of recur-
sive self-invalidation of the system,24 in which the activation
of a specific emotion (specially anger and sadness) supposes
the invalidation of identity aspects of the self. The objective
is to revise the meaning-construction system in such a way
that emotions are acceptable, compatible rather than invali-
dating for the self-identity system. The techniques used
include the explanation of the dilemma (psychoeducation
about the emotions); the historical revision of the emotional
dilemma, hypnosis, etc.
Complaints Focused on Interpersonal Conflicts
These conflicts can be related to FM or to other issues. By
exploring the patients’ views about these problems, often
some difficulties in sociality,23 which refers to their capa-
city to construe the construction processes of another
person in a meaningful way, can be observed. The objec-
tive is to extend the meaning-construction system in such
a manner that it can offer possible action courses that are
compatible with the sense of identity of the patient.
Possible techniques to increase sociality include represen-
tations of the family as sculptures;46 use of analogical
resources such as metaphors; and the inclusion of some
members of the family in some of the sessions, etc.
Ambivalent Complaints About Change
In these cases, the therapist has identified the presence of
one or more implicative dilemmas in the RGT of the
participant.47 The change has ambivalent implications,
which means that a change movement towards the desired
pole of the construct (eg, “being happy” instead of “being
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sad”) implies a significant change in other constructs that are
congruent with the personal identity (eg, “being happy”
implies to “be selfish” instead of “generous”). The objective
is to resolve the dilemma, so the desired change does not
imply a threat to the sense of identity. The intervention will
follow the guidelines provided by Feixas and Compañ.37
Treatment Integrity
Both treatment conditions will be conducted by psy-
chotherapists trained in the specific treatment condition
that they apply. However, before to be part of the trial, all
therapists will attend to a specific training in the proto-
cols used in this study. Senior therapists with at least 10
years of clinical experience will carry out the training;
also, they will supervise the psychotherapeutic process
and the adherence to intervention protocols for each
treatment condition. All therapy sessions will be
recorded to verify treatment integrity and to supervise
the development of the psychotherapeutic process. The
therapist or supervisor will report to the research team
any deviation of the intervention protocol for recording
in the database. After the completion of the study, the
content of 10% of the total number sessions for each
condition will be randomly selected to be monitored
and assessed in order to verify the adherence to the
guidelines for each specific treatment condition. The
conclusions of this assessment will be included in the
report of the results of the trial.
Measures
Primary Outcome Measure
Depression Items of the Hospital Anxiety and Depression
Scale (HADS-D)40,48
To assess the symptoms of depression other than somatic
problems such as insomnia or fatigue, which can be pre-
sent in FM patients. It has seven items related to depres-
sion, and they are rated in a four-point Likert scale. This
instrument has acceptable psychometric properties48 and it
has shown to be useful with FM patients.49–51 The anxiety
items of the HADS will be considered as a secondary
outcome measure.
Secondary Outcome measures
Hamilton Depression Rating Scale (HDRS)52,53
To evaluate the severity of depressive symptoms, it is rated
by the clinician after a clinical interview. The scale contains
17 items, and it has shown good psychometric properties.53
Fibromyalgia Impact Questionnaire (FIQ)54,55
To assess the impact of FM on physical functioning,
development of daily tasks, and pain-related symptoms.
It has shown good psychometric properties and sensitivity
to change after treatment.56
Anxiety Items of the Hospital Anxiety and Depression
Scales (HADS-A)40,48
To assess the symptoms of anxiety in FM patients avoid-
ing dependency on somatic aspects.
Visual Analogue Scale for Pain (VAS Pain)57
To assess the intensity of pain session by session, it is a 100mm
long horizontal straight line, marked at one end with the label
“no pain” and the opposite end with the label “worst possible
and unbearable pain”. Scores range from 0 to 100. This scale is
widely used in clinical practice and research.58
Clinical Outcomes in Routine Evaluation – Outcome
Measure (CORE-OM)59,60
This is a 34-item self-reported questionnaire designed to
assess the change in therapy (pre-post) which evaluates
four dimensions: subjective well-being, symptoms or pro-
blems, life functioning and risk. It has shown good psy-
chometric properties. The brief version of 18 items
(CORE-SFB) is used at the beginning of each session.
Repertory Grid Technique (RGT)23,28,29,61
To assess cognitive structure, self-concept and cognitive
conflicts, PCT provides this semi-structured interview
focused on the elicitation of bipolar personal constructs
and their assessment as they are applied to significant others
(elements). Then, every element is rated according to each
construct using a 7-point Likert scale. The statistical analysis
of the resulting data matrix generates cognitive indexes,
distances between different perceptions of the self, and
number and intensity of cognitive conflicts (if any). The
information given by the RGT is useful for planning the
psychotherapeutic process conducted by means of the PCT.
Procedure
Professionals of collaborating centers will be informed about
the study and asked to offer participation to the relevant
patients. After referral, potential participants are contacted
to arrange a date for the initial assessment (t1). It begins
explaining the study to participants and offering them to
sign the informed consent.
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After random allocation to treatment, and once the treat-
ment is completed (maximum 18 sessions), the second
assessment (t2) with all the baseline measures will be con-
ducted by the same evaluators who carried out the baseline
assessment (whenever possible). A follow-up assessment (t3)
will be conducted 6 months after the termination of the
treatment (see Table 1 for a detailed schedule of assessments
and interventions according to SPIRIT recommendations62).
The evaluators are blind to the therapeutic condition of the
assessed participant. Participant’s allocated intervention will
not be revealed to evaluators in any circumstance. Treatments
will be discontinued in case of participant request.
Data Management
Participant data files with personal data are stored in a locked
filing cabinet at the University of Barcelona accessible only
to one member of the research team who supervises data
entry and controls the access to the personal data file. Data
integrity checks will be conducted to check completeness
using spot checks, and consistency will be tested using
Table 1 SPIRIT Diagram of Assessments at Baseline (t1), Allocation (0), Weekly Sessions (s1–s18), Treatment Termination (t2), Booster
Sessions (t2+3m - t2+5m) and 6-Month Follow-Up (t3)
STUDY PERIOD
Baseline Allocation Post-allocation Follow-up
TIMEPOINT t1 0 s1 sn…18 t2 t2+ 3m t2+4m t2+5m t3
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation/
Randomization
X
INTERVENTIONS:
PCT X X X
CBT X X X
ASSESSMENTS:
Sociodemographic and 
clinical information
X
HADS-D X X X
HADS-A X X X
HDRS X X X
FIQ X X X
RGT X X X
CORE-OM X X X
CORE-SFB a X X X
VAS Pain a X X X
Note: aQuestionnaires applied every session.
Abbreviations: PCT, Personal Construct Therapy; CBT, Cognitive Behavioral Therapy; HADS-D, Hospital Anxiety and Depression Scale – Depression; HADS-A, Hospital
Anxiety and Depression Scale – Anxiety; HDRS, Hamilton Depression Rating Scale; FIQ, Fibromyalgia Impact Questionnaire; RGT, Repertory Grid Technique; CORE-OM,
Clinical Outcomes in Routine Evaluation – Outcome Measure; CORE-SFB, Clinical Outcomes in Routine Evaluation – Short Form B; VAS Pain, Visual Analogue Scale for Pain.
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plausibility checks. The interventions suppose minimal risk
for the participants, then there will not be a data monitoring
committee for this study. Once completed the study and the
integrity checks, data will be made available in a public
repository for open access. Participants’ privacy will be
protected by excluding any identifying personal data accord-
ing to ethical standards about data sharing.
Statistical Analyses
Intention-to-treat and complete case analyses will be per-
formed for the main statistical comparisons. Linear mixed
models will be used to analyze and to compare the treatment
effects of conditions. Baseline measurements, sociodemo-
graphic, clinical variables and number of sessions will be
entered in the model as covariates, while outcome measure-
ments will be the dependent variables. Potential moderator
role of the cognitive measures obtained by the RGTwill be
explored, especially those reflecting cognitive conflicts. For
all the analyses, effect sizes will be calculated. To accept the
hypothesis that the PCT is superior than CBT, the effect size
when comparing both treatments at the end of the interven-
tion and at follow-up must be at least 0.30, demonstrating
that the reduction of depressive symptoms is greater in PCT
than in CBT condition.
CORE-OM will permit to assess the degree of thera-
peutic change regarding psychological distress, psychoso-
cial functioning and suicide risk. In addition, the
application of CORE-SFB and VAS Pain in each session
will allow to assess the trajectories of change experienced
and the percentage of change session by session.
The proportion of patients who attain clinically signifi-
cant improvement on the outcome measures (HDRS,
HADS-D, HADS-A, FIQ and CORE-OM) will be calcu-
lated and compared between treatment conditions.
Clinically significant change will be calculated considering
the proposal of Jacobson and Truax.63 To test the differ-
ences in frequencies between the two intervention condi-
tions, chi-square tests will be applied.
Patient and Public Involvement
The input received from patients participating in the pilot
study35 guided the design and the creation of the treatment
protocols for the present study. In the current trial, the
patients were not involved in the design of the study nor
in the selection of the outcome measures.
Discussion
Depressive symptoms are present in a great proportion of
patients with FM, these symptoms exacerbate its clinical and
socio-economic consequences. Thus, depressive symptoms
constitute one of the principal therapeutic targets for the treat-
ment of patients with FM. Psychological treatments have
demonstrated some efficacy in the treatment of depression in
patients with FM. CBT, usually applied in group format, has
accumulated enough evidence to be recommended as
a treatment of choice in reviews and clinical guidelines; how-
ever, there is no evidence that this treatment acquires symp-
toms resolution. The limitations on reducing depressive
symptoms in FMpatientsmight be a product of the complexity
of the syndrome and the resulting lack of treatment specificity.
Then, an individual treatment that considers the needs and
psychological profiles of each patient is needed. PCT might
meet these requirements because it focuses on personal identity
reconstruction and themeanings around significant others.One
limitation of our study is that the generalization of the findings
will be limited to women. Although FM is much more pre-
valent in women, the study will not provide any solid grounds
to increase our knowledge about the treatment of this syn-
drome for male patients. Further studies are much needed in
the future to address this issue.
Conclusion
The aim of this trial is to test the hypothesis that PCT might
contribute to increase the efficacy in the reduction of
depressive symptoms in patients with FM. We do not con-
sider that cognitive conflicts are the cause or the principal
factor of maintenance of depressive symptoms, but we
believe that patients with dilemmas make depressive symp-
toms congruent with one part of their cognitive system
(while it is undesirable for the other part). Whenever these
dilemmas are detected, they might become the objective of
the treatment. Cognitive conflicts are usually neglected by
well-established treatments such as CBT.
By including in the research team members of different
theoretical orientations (with extensive clinical experience in
the treatment modalities being tested in the study), we aimed
to minimize the potential allegiance bias described in the
psychotherapy outcome research literature. If PCT reduces
depressive symptoms, it might be considered as part of
a multimodal approach, and recommended by the clinical
guidelines. The efficacy of PCT as part of a multimodal
treatment should be precisely gauged in future studies.
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Abbreviations
FM, Fibromyalgia; PCT, Personal Construct Therapy; CBT,
Cognitive Behavioral Therapy; RGT, Repertory Grid
Technique; HADS-D, Depression items of the Hospital
Anxiety and Depression Scale; HADS-A, Anxiety items of the
Hospital Anxiety and Depression Scale; HDRS, Hamilton
Depression Rating Scale; FIQ, Fibromyalgia Impact
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